naa a22 4500 510763553 CHVBK 20180411083148.0 cr unu---uuuuu 180411e20130701xx s 000 0 eng 10.1007/s12094-012-0981-1 doi (NATIONALLICENCE)springer-10.1007/s12094-012-0981-1 Optimal management of breakthrough cancer pain (BCP) [Elektronische Daten] [Y. Escobar, A. Mañas, J. Juliá, R. Gálvez, F. Zaragozá, C. Margarit, R. López, A. Casas, A. Antón, J. Cruz] Breakthrough cancer pain (BCP) is common in patients with cancer, causing a negative impairment in quality of life. Recent diagnostic criteria allow for differentiation of background chronic pain and BCP, for which proportion of unpredictable episodes is very high. Five characteristics define BCP: rapid onset, high intensity, maximum intensity (minutes), mean duration 30min, and unpredictable onset. Fentanyl is a synthetic opioid characterized by rapid absorption and start of the analgesic effects. In addition to comparing some of the marked differences between the four pharmaceutical forms of fentanyl marketed in Spain, this paper discusses the data collected in a comprehensive clinical trial program with fentanyl pectin nasal spray (FPNS), a formulation that takes advantage of the intranasal route and the PecSys™ technology. The FPNS formulation achieves analgesic action 5min after application and significant pain relief at 10min. FPNS, therefore, has key features to be an optimal treatment for BCP. Federación de Sociedades Españolas de Oncología (FESEO), 2012 Breakthrough cancer pain (BCP) nationallicence Management nationallicence Fentanyl nationallicence Intranasal administration nationallicence Escobar Y. Department of Medical Oncology, Gregorio Marañón General University Hospital, Madrid, Spain aut Mañas A. Department of Oncology-Radiotherapy, Hospital Universitario La Paz, Madrid, Spain aut Juliá J. Department of Integral Support and Palliative Care, Institut Català d'Oncologia (ICO) Badalona, Hospital Universitari Germans Trias i Pujol, Badalona, Spain aut Gálvez R. Unit of Pain and Palliative Care, Hospital Virgen de las Nieves, Granada, Spain aut Zaragozá F. Department of Pharmacology, Alcalá de Henares University, Madrid, Spain aut Margarit C. Pain Unit, Alicante University General Hospital, Alicante, Spain aut López R. Department of Medical Oncology, University Hospital Complex, Santiago de Compostela, Spain aut Casas A. Department of Medical Oncology, Hospital Virgen de la Macarena, Sevilla, Spain aut Antón A. Department of Medical Oncology, Miguel Servet Hospital, Zaragoza, Spain aut Cruz J. Department of Medical Oncology, Salamanca University Hospital, Salamanca, Spain aut Clinical and Translational Oncology Springer Milan 15/7(2013-07-01), 526-534 1699-048X 15:7<526 2013 15 12094 https://doi.org/10.1007/s12094-012-0981-1 text/html Onlinezugriff via DOI 1 review-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/s12094-012-0981-1 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Escobar Y. Department of Medical Oncology, Gregorio Marañón General University Hospital, Madrid, Spain aut NATIONALLICENCE 700 1- Mañas A. Department of Oncology-Radiotherapy, Hospital Universitario La Paz, Madrid, Spain aut NATIONALLICENCE 700 1- Juliá J. Department of Integral Support and Palliative Care, Institut Català d'Oncologia (ICO) Badalona, Hospital Universitari Germans Trias i Pujol, Badalona, Spain aut NATIONALLICENCE 700 1- Gálvez R. Unit of Pain and Palliative Care, Hospital Virgen de las Nieves, Granada, Spain aut NATIONALLICENCE 700 1- Zaragozá F. Department of Pharmacology, Alcalá de Henares University, Madrid, Spain aut NATIONALLICENCE 700 1- Margarit C. Pain Unit, Alicante University General Hospital, Alicante, Spain aut NATIONALLICENCE 700 1- López R. Department of Medical Oncology, University Hospital Complex, Santiago de Compostela, Spain aut NATIONALLICENCE 700 1- Casas A. Department of Medical Oncology, Hospital Virgen de la Macarena, Sevilla, Spain aut NATIONALLICENCE 700 1- Antón A. Department of Medical Oncology, Miguel Servet Hospital, Zaragoza, Spain aut NATIONALLICENCE 700 1- Cruz J. Department of Medical Oncology, Salamanca University Hospital, Salamanca, Spain aut NATIONALLICENCE 773 0- Clinical and Translational Oncology Springer Milan 15/7(2013-07-01), 526-534 1699-048X 15:7<526 2013 15 12094 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer